Clearance Summary
Cell-Free DNA BCT received FDA 510(k) clearance under submission number K231776, sponsored by Streck, Inc.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 2024-07-26.
- Submission: K231776
- Applicant / Sponsor: Streck, Inc.
- Clearance pathway: Traditional
- Review panel: Clinical Chemistry
- Device class: Class II
- Regulation citation: 21 CFR 862.1676
- Decision date: 2024-07-26
Classification & Regulation
This clearance is catalogued under FDA product code QMA and 21 CFR 862.1676, within the Clinical Chemistry review panel as a Class II device.